Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2014

01-10-2014 | Research Article

Improved venous thromboembolism prophylaxis by pharmacist-driven interventions in acutely ill medical patients in Belgium

Authors: Audrey Vervacke, Sophie Lorent, Serge Motte

Published in: International Journal of Clinical Pharmacy | Issue 5/2014

Login to get access

Abstract

Background Forty to 50 % of hospitalized patients with an acute medical illness have risk factors for venous thromboembolism (VTE) and it has been shown that VTE prophylaxis reduced the incidence of VTE events in these patients. However, a large multinational survey, the ENDORSE study, showed that only 37 % of medical patients with VTE risk factors actually received VTE prophylaxis. Objective To evaluate the impact over time of pharmacist-driven interventions aiming at increasing the appropriate use of VTE prophylaxis in acutely ill medical hospitalized patients. Setting A Belgian urban academic hospital. Method First, during 1 month, medical and nurse reports of all hospitalized medical patients were reviewed to evaluate the proportion of patients who were on prophylaxis according to clinical practice guidelines. Second, interventions were conducted and included unit-specific physician and nurse education, diffusion of educational tools summarizing VTE prophylaxis guidelines, and reminders. Third, the impact of the interventions on the proportion of patients receiving VTE prophylaxis according to clinical practice guidelines was evaluated after 3 months and 1 year. Main outcome measure Proportion of hospitalized medical patients receiving VTE prophylaxis according to clinical practice guidelines. Results The baseline evaluation showed that 36 % (26/72) of the patients at risk of VTE received VTE prophylaxis according to clinical practice guidelines. Three months and one year after the interventions, 68 % (55/81), and 72 % (58/81) of the patients at risk of VTE received VTE prophylaxis according to clinical practice guidelines. Among patients not at risk of VTE, 15 % (21/141), 8 % (24/290), and 8 % (27/330) respectively at baseline evaluation, 3 months and 1 year after the interventions, received VTE prophylaxis. Conclusion Pharmacist-driven interventions improved the proportion of acutely ill medical patients receiving VTE prophylaxis according to clinical practice guidelines and the benefit of the interventions was maintained after 1 year.
Literature
1.
go back to reference Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387–94.PubMedCrossRef Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387–94.PubMedCrossRef
2.
go back to reference Anderson FA Jr, Zayaruzny M, Heit JA, Fidan D, Cohen AT. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol. 2007;82:777–82.PubMedCrossRef Anderson FA Jr, Zayaruzny M, Heit JA, Fidan D, Cohen AT. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol. 2007;82:777–82.PubMedCrossRef
3.
4.
go back to reference Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med. 1989;82(4):203–5.PubMedPubMedCentral Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med. 1989;82(4):203–5.PubMedPubMedCentral
7.
go back to reference Dentali F, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007;146(4):278–88.PubMedCrossRef Dentali F, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007;146(4):278–88.PubMedCrossRef
8.
go back to reference Schädlich PK, Kentsch M, Weber M, et al. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany. Pharmacoeconomics. 2006;24(6):571–91.PubMedCrossRef Schädlich PK, Kentsch M, Weber M, et al. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany. Pharmacoeconomics. 2006;24(6):571–91.PubMedCrossRef
9.
go back to reference Yu HT, Dylan ML, Lin J, Dubois RW. Hospitals’ compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm. 2007;1:69–76.CrossRef Yu HT, Dylan ML, Lin J, Dubois RW. Hospitals’ compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm. 2007;1:69–76.CrossRef
10.
go back to reference Gould M, Garcia D, Wren S, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence based clinical practice guidelines. Chest. 2012;141(2_suppl):e227S–77S.PubMedCrossRefPubMedCentral Gould M, Garcia D, Wren S, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence based clinical practice guidelines. Chest. 2012;141(2_suppl):e227S–77S.PubMedCrossRefPubMedCentral
11.
go back to reference Falck-Ytter Y, Francis C, Johanson N, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2_suppl):e278S–325S.PubMedCrossRefPubMedCentral Falck-Ytter Y, Francis C, Johanson N, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2_suppl):e278S–325S.PubMedCrossRefPubMedCentral
12.
go back to reference Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S–453S.PubMedCrossRef Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S–453S.PubMedCrossRef
13.
go back to reference Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153:8–18. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153:8–18.
14.
go back to reference Dobesh P, Phillips K, Haines S. Improving the use of anticoagulant therapies in acutely ill medical patients. Am J Health Syst Pharm. 2008;65(suppl 7):s5–12.PubMedCrossRef Dobesh P, Phillips K, Haines S. Improving the use of anticoagulant therapies in acutely ill medical patients. Am J Health Syst Pharm. 2008;65(suppl 7):s5–12.PubMedCrossRef
15.
go back to reference Bauer J, Chun D, Karpinski T. Pharmacist-led program to improve venous thromboembolism prophylaxis in a community hospital. Am J Health Syst Pharm. 2008;65:1643–7.PubMedCrossRef Bauer J, Chun D, Karpinski T. Pharmacist-led program to improve venous thromboembolism prophylaxis in a community hospital. Am J Health Syst Pharm. 2008;65:1643–7.PubMedCrossRef
16.
go back to reference Khalili H, et al. Is deep vein thrombosis prophylaxis appropriate in the medical wards? A clinical pharmacist’s intervention study. Pharm World Sci. 2010;32:594–600.PubMedCrossRef Khalili H, et al. Is deep vein thrombosis prophylaxis appropriate in the medical wards? A clinical pharmacist’s intervention study. Pharm World Sci. 2010;32:594–600.PubMedCrossRef
17.
go back to reference Semchuk W, Kolodziejak L, Bubbar C, Poulin S. Working toward a system-wide venous thromboembolism prophylaxis strategy: experience from a multisite health region. Hosp Pharm. 2011;46(8):574–9.CrossRef Semchuk W, Kolodziejak L, Bubbar C, Poulin S. Working toward a system-wide venous thromboembolism prophylaxis strategy: experience from a multisite health region. Hosp Pharm. 2011;46(8):574–9.CrossRef
18.
go back to reference Sobieraj D. Development and implementation of a program to assess medical patients’ need for venous thromboembolism prophylaxis. Am J Health syst Pharm. 2008;65:1755–61.PubMedCrossRef Sobieraj D. Development and implementation of a program to assess medical patients’ need for venous thromboembolism prophylaxis. Am J Health syst Pharm. 2008;65:1755–61.PubMedCrossRef
19.
go back to reference Nendaz MR, Chopard P, Lovis C, Kucher N, Asmis LM, Dörffler J, Spirk D, Bounameaux H. Adequacy of venous thromboprophylaxis in acutely ill medical patients (IMPART): multisite comparison of different clinical decision support systems. J Thromb Haemost. 2010;8(6):1230–4.PubMedCrossRef Nendaz MR, Chopard P, Lovis C, Kucher N, Asmis LM, Dörffler J, Spirk D, Bounameaux H. Adequacy of venous thromboprophylaxis in acutely ill medical patients (IMPART): multisite comparison of different clinical decision support systems. J Thromb Haemost. 2010;8(6):1230–4.PubMedCrossRef
20.
go back to reference Chopard P, Dörffler-Melly J, Hess U, Wuillemin WA, Hayoz D, Gallino A, Bachli EB, Canova CR, Isenegger J, Rubino R, Bounameaux H. Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement. J Intern Med. 2005;257(4):352–7.PubMedCrossRef Chopard P, Dörffler-Melly J, Hess U, Wuillemin WA, Hayoz D, Gallino A, Bachli EB, Canova CR, Isenegger J, Rubino R, Bounameaux H. Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement. J Intern Med. 2005;257(4):352–7.PubMedCrossRef
Metadata
Title
Improved venous thromboembolism prophylaxis by pharmacist-driven interventions in acutely ill medical patients in Belgium
Authors
Audrey Vervacke
Sophie Lorent
Serge Motte
Publication date
01-10-2014
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 5/2014
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-014-9988-8

Other articles of this Issue 5/2014

International Journal of Clinical Pharmacy 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine